Dextran-Mannose Therapeutic Compounds for Specific Macrophage Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting and treating diseases mediated by mannose-binding C-type lectin receptor-high expressing cells, such as macrophages, are limited in specificity and efficacy, particularly in conditions like autoimmune diseases, inflammatory diseases, and cancers.
Innovation Solution
Development of compounds comprising a dextran backbone with mannose-binding C-type lectin receptor targeting moieties and therapeutic agents, which selectively target and bind to cells like macrophages, allowing for diagnostic and therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents are used, then treatment can be provided, but specificity and efficacy in targeting macrophages is limited
Solution Approach 1:
The compound is divided into distinct functional segments: a dextran backbone providing structural framework, mannose moieties providing target-specific binding to CD206 receptors on macrophages, and therapeutic agent moieties providing treatment function. This segmentation allows each component to perform its specialized function, achieving high specificity for macrophage targeting while maintaining manageable structural complexity through modular design.
Solution Approach 2:
The invention creates a composite compound combining dextran (a polysaccharide), mannose (a monosaccharide), and therapeutic agents (various pharmacological compounds). This composite structure leverages the specific properties of each material: dextran provides solubility and stability, mannose provides selective binding to macrophage CD206 receptors, and the therapeutic agents provide disease-treating activity. The composite nature enables simultaneous achievement of specificity and efficacy.
2Reliability
If conventional therapeutic agents are used, then treatment can be provided, but efficacy in treating diseases mediated by macrophages is limited
Solution Approach 1:
The compound exhibits local quality through the strategic placement of mannose moieties at specific locations on the dextran backbone. These mannose units are positioned to maximize interaction with CD206 receptors on macrophage surfaces. The therapeutic agents are also strategically attached to ensure delivery to the target cells. This localized functional arrangement enhances efficacy by concentrating the therapeutic action precisely where needed - at the macrophage cell surface and interior - while the overall compound structure remains systematically organized.
3Measurement precision
If non-specific therapeutic agents are used, then treatment coverage is broad, but targeting precision for mannose-binding C-type lectin receptor-high expressing cells is insufficient
Solution Approach 1:
The compound achieves universality by combining a universal targeting mechanism (mannose binding to CD206 receptors) with multiple potential therapeutic agent options. The dextran-mannose core structure provides universal macrophage targeting capability that can be applied across different diseases. Meanwhile, the therapeutic agent portion can be customized from various pharmacological compounds depending on the specific disease indication, such as anti-inflammatory agents for autoimmune diseases, anti-cancer agents for malignancies, or anti-infective agents for infections. This multi-functional design enables both high targeting precision and broad disease treatment range.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively diagnose and treat diseases by selectively targeting mannose-binding C-type lectin receptor-high expressing cells, providing therapeutic agents that can induce apoptosis in these cells and improve disease outcomes.
Implementation Method 1
Tilmanocept has a small molecular size (7 nanometers) and carries multiple units of mannose. This mannose component has a high affinity for mannose-binding C-type lectin receptor proteins, such as CD206 and CD209, which are found in high concentrations on the surface of macrophages, dendritic cells and other cells. By tightly binding to these mannose receptors, Tilmanocept accumulates in lymphatic tissue within minutes and localizes in tumor-draining lymph nodes.
Data Source
AI summary
Provided are compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treatment and diagnosis using such compounds and compositions.